Merck bolsters neurodegeneration program with Caraway acquisition

Companies agree deal worth up to $610m for preclinical pipeline targeting genetically defined neurodegenerative diseases.
Preclinical biopharma Caraway Therapeutics is to be acquired by pharma giant Merck in a deal worth up to $610 million. The companies revealed that a…Read More

Loyal gets promising FDA feedback on lifespan extension drug for dogs

Company founder says FDA has formally accepted that a drug can be developed and approved to extend lifespan.
In a blog post this week, Celine Halioua, the founder and CEO of dog longevity biotech Loyal, revealed that the company has received what it believes to be the…Read More

Biolexis lands $10m to advance metabolic drug program with longevity potential

Company is developing metabolic drug candidates targeting obesity, diabetes and human longevity.
AI-driven drug discovery company Biolexis Therapeutics has closed a $10 million Series A funding round, supporting its mission to advance metabolic drug development.…Read More

Interface Bio emerges with $3m to harness the microbiome against inflammation

AI-powered platform identifies bacterial natural products with the potential to modulate the immune system and reduce inflammation.
Biotech startup Interface Biosciences has secured $3 million in an oversubscribed seed funding round to advance its AI drug discovery…Read More

Insilico announces first-in-human study for oral PHD inhibitor for IBD

Biotech aims to accelerate clinical trials to reach unmet clinical needs for inflammatory bowel disease.
Insilico Medicine, a generative AI-driven clinical-stage biotech, has announced it has initiated the first-in-human study for ISM5411, a potentially first-in-class PHD…Read More

Stanford organ aging study spawns new longevity startup

Teal Omics founded after researchers develop algorithm that measures how fast individual organs are aging.
A study led by researchers from Stanford Medicine, published this week in Nature, has unveiled a new method to predict the biological aging rates of individual organs. By analyzing…Read More

EyePoint raises $230 million following positive AMD trial results

Company targets Phase 3 trial in 2024 after wet AMD treatment achieves ‘statistical non-inferiority’ compared with aflibercept in Phase 2.
Retinal health biotech EyePoint Pharmaceuticals (NASDAQ: EYPT) has closed an underwritten public offering of shares of its common stock, rai…Read More

MitoRx raises $5 million to advance mitochondrial dysfunction therapeutics
Author: Danny Sullivan | Published on: December 13, 2023 | Last updated: December 13, 2023

Early data shows company’s lead asset ‘preserves strength in oxidative muscle and confirms mitochondrial modulation.’
British longevity biotech MitoRx Therapeutics has concl…Read More